CSK and malignant colon neoplasm: In HT-29 colon cancer cells, isorhamnetin’s chemoprotective properties against colon cancer are attributed to its anti-inflammatory activity as well as its inhibition of Src-mediated carcinogenesis, leading to the subsequent loss of nuclear beta catenin that relies on CSK expression (19).